Table 2.
Network meta-analysis results in BCVA and CMT at 3 months (lower part) and 6 months (upper part).
| TA | -0.36 (-0.6, -0.12) |
-0.14 (-0.37, 0.09) |
-0.78 (-1.05, -0.51) |
0.34
(0.05, 0.65) |
0.54
(0.15, 0.93) |
0.62
(0.35, 0.87) |
0.54
(0.15, 0.93) |
- | |
| 0.07 (-0.39, 0.55) |
-0.54 (-1, -0.16) |
-0.46 (-0.92, -0.02) |
-0.15 (-0.75, 0.39) |
1.60
(1.03, 2.24) |
- | 0.34 (-0.42, 1.01) |
0.55 (-0.43, 1.61) |
||
| -0.01 (-0.35, 0.33) |
IVB | 0.21 (-0.08, 0.51) |
-0.42 (-0.76, -0.08) |
0.69
(0.36, 1.06) |
0.90
(0.50, 1.33) |
0.97
(0.72, 1.23) |
0.91
(0.50, 1.33) |
- | |
| 0.41 (-0.06, 0.73) |
-0.61 (-1.29, -0.02) |
-0.53 (-1.12, 0.04) |
-0.22 (-1.01, 0.48) |
1.52
(1.01, 2.09) |
- | 0.27 (-0.65, 1.07) |
0.48 (-0.48, 1.5) |
||
| -0.25 (-0.58, 0.07) |
-0.25 (-0.68, 0.21) |
LP | -0.63 (-0.98, -0.29) |
0.49
(0.32, 0.68) |
0.69
(0.4, 0.98) |
0.76
(0.49, 1.02) |
0.69
(0.37, 0.98) |
- | |
|
-0.76
(-1, -0.51) |
-1.17
(-1.54, -0.75) |
0.07 (-0.5, 0.73) |
0.39
(0.02, 0.77) |
2.13
(1.47, 2.95) |
- |
0.87
(0.30, 1.44) |
1.09
(0.06, 2.28) |
||
|
-0.87
(-1.14, -0.59) |
-0.87
(-1.25, -0.45) |
-0.63
(-1.02, -0.19) |
Placebo |
1.21
(0.73, 1.52) |
1.32
(0.88, 1.78) |
1.39
(1.05, 1.75) |
1.32
(0.88, 1.78) |
- | |
|
-0.74
(-1.02, -0.47) |
-1.14
(-1.49, -0.78) |
0.02 (-0.34, 0.38) |
0.32 (-0.45, 1.01) |
2.07
(1.52, 2.70) |
- | 0.80 (-0.09, 1.6) |
1.01
(0.05, 2.08) |
||
| 0.01 (-0.37, 0.37) |
0.01 (-0.45, 0.49) |
0.26 (0.02, 0.48) |
0.88 (0.41, 1.31) |
TA+LP | 0.21 (-0.14, 0.53) |
0.28 (-0.06, 0.59) |
0.21 (-0.14, 0.53) |
- | |
|
-0.43
(-0.73, -0.16) |
0.64 (-0.41,1.24) |
0.33 (0.18, 0.47) |
0.31 (-0.08, 0.69) |
1.74
(0.98, 2.65) |
- | 0.48 (-0.21, 1.17) |
0.69 (-0.4, 1.96) |
||
|
-0.59
(-1.01, -0.26) |
-0.60
(-1.05, -0.18) |
-0.37 (-0.86, 0.1) |
0.27 (0.09, 0.51) |
0.62 (0.12,1.14) | DEX |
0.67
(0.29, 1.04) |
0.58
(0.12, 1.07) |
- | |
| -0.01 (-0.4, 0.36) |
-0.42
(-0.89, -0.07) |
0.75 (0.48, 1.02) |
0.73 (0.27, 1.18) |
0.42 (-0.12, 0.74) |
- | -1.26 (-2.28, -0.4) |
-1.04 (-1.87, -0.21) |
||
| 0.34 (0.05, 0.74) |
0.34 (-0.06, 0.77) |
0.59 (0.17, 1.01) |
1.18 (0.74, 1.66) |
0.33 (-0.13, 0.8) |
0.95 (0.46, 1.49) |
IVB+TA | -0.08 (-0.45, 0.32) |
- | |
| 1.00 (-0.7, 1.34) |
0.61 (-0.26, 0.98) |
-0.79 (-1.38, 0.18) |
-0.49
(-1.02, -0.6) |
-0.47 (-1.04, 0.18) |
-1.05
(-1.52, -0.54) |
- | - | ||
| 0.19 (-0.37, 0.75) |
0.19 (-0.43, 0.84) |
0.44 (-0.01, 0.89) |
1.06 (0.43, 1.66) |
0.19 (-0.32, 0.69) |
0.80 (0.17, 1.49) |
-0.15
(-0.77, -0.01) |
DEX+LP | - | |
| -0.13 (-0.5, 0.21) |
-0.54 (-0.97, 0.08) |
0.62 (0.35, 0.9) |
0.60 (-0.16, 1.03) |
0.29 (-0.01, 0.6) |
-0.13
(-0.51, -0.05) |
-0.27 (-0.7,1.63) |
0.21 (-0.95, 1.56) |
||
|
-0.83
(-1.45, -0.3) |
-0.83
(-1.47, -0.25) |
-0.59 (-1.27, 0.03) |
0.13 (-0.55, 0.5) |
-0.85
(-1.54, -0.2) |
-0.23 (-0.66, 0.21) |
-1.18
(-1.88, -0.53) |
-1.03
(-1.86, -0.28) |
IVA | |
| 0.71 (0.27, 1.11) |
0.31 (-0.15, 0.74) |
1.06 (0.98, 1.93) |
1.45 (1.07, 1.77) |
1.14 (0.64, 1.63) |
-0.72
(-1.26, -0.14) |
0.33 (0.05, 0.6) |
0.84 (-0.3, 1.38) |
IVR | |
*TA, intravitreal triamcinolone; IVB, intravitreal bevacizumab; LP, laser, macroscopic laser, grid laser and focal/grid laser; TA+LP, intrareal triamcinolone combined with laser; DEX, intravitreal dexamethasone; IVB+TA, intravitreal bevacizumab combined with triamcinolone; DEX+LP, intrareal dexamethasone combined with laser; IVR, intravitreal ranibizumab; IVA, intravitreal affiliation.
The blue represents for BCVA and green represents CMT. The bold values represent for P<0.05.